Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immuron Ltd (IMC.AX)

Immuron Ltd (IMC.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Immuron Ltd 25-37, Chapman Street Unit 10 Melbourne VIC 3130 AUS

https://www.immuron.com.au P: +61 388924854

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Key Statistics

Overview:

Market Capitalization, $K 13,256
Shares Outstanding, K 323,321

Financials:

Annual Sales, $ 7,287 K
Annual Net Income, $ -5,216 K

Growth:

1-Year Return -55.68%
3-Year Return -48.10%
5-Year Return 0.00%
5-Year Revenue Growth 23.67%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.02
Dividend Payout Ratio 0.00%
Most Recent Split 1-40 on 11/17/14

IMC.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -50.21%
Return-on-Assets % -40.62%
Profit Margin % -71.58%
Debt/Equity 0.01
Price/Sales 1.30
Price/Book 1.64
Book Value/Share 0.03
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar